1 / 9

Implementation of the E5 Guideline: Status and Next Steps

Implementation of the E5 Guideline: Status and Next Steps. ICH and GCG. International leadership role in scientific harmonization Requirements for drug development must have a scientific basis Value of harmonization of regulations Brings innovative medicines to patients faster

yoko
Télécharger la présentation

Implementation of the E5 Guideline: Status and Next Steps

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Implementation of the E5 Guideline:Status and Next Steps

  2. ICH and GCG • International leadership role in scientific harmonization • Requirements for drug development must have a scientific basis • Value of harmonization of regulations • Brings innovative medicines to patients faster • Reduces delays in drug development • Minimizes duplication of clinical studies • GCG: Outreach to non-ICH countries • ICH can add value in non-ICH countries • ICH is recognizing this value by expanding its activities

  3. E5 • Prospective harmonization to: • Reduce duplicative clinical testing • Minimize delays in drug development • Aimed at facilitating registration of ‘legacy’ medicines in ICH regions • Implementation is complex! • Focus today must be relevance of E5 to public health and global drug development

  4. E5 and Global Development • Large, multi-center, multi-ethnic clinical development programs • Inter- individual > inter-ethnic differences • Data extrapolation often possible • Bridging studies conducted less frequently • Harmonized E5 implementation is critical

  5. E5 Principles • 3 ethnic groups– Asian, Black, Caucasian • Country-specific studies are not scientifically justified • Internationally accepted approach is critical • Scientific methodology • Regulatory process • Bridging studies should only be conducted if scientifically necessary

  6. E5 Criteria • Steps in assessing the need for bridging • Can the existing data be extrapolated to the new population? • If not, are the differences that exist clinically relevant? • If they are, what study is required to allow the data to be extrapolated? This is the bridging study • Steps 1 and 2 are ‘bridging justification’

  7. E5 Implementation • Must not cause disharmony among regulators • Requires • Sound science-based assessment of Clinical Data Package and relevance to new region (‘bridging justification’) • Well-defined regulatory process • Statistics has a role, but must consider • Statistical significance vs significance to patients and public policy • Questions that need to be answered before statistics are used • Clinical relevance is key

  8. Regulatory Environment • Support innovation and public health • Science based • internationally harmonized scientific standards • Well-structured, consistent and transparent • E5 – early binding consultations • External advisory committee for appeals during approval process

  9. Next Steps • ICH is addressing implementation issues in a Q&A • Continued dialogue between regulators and industry is critical • At all levels: company-national regulator; industry-national regulator; industry-regulator across countries • Global drug development will eventually obviate the E5 guideline • We must continue to address E5 implementation • At the same time, we must start to address issues of global drug development • We all have a public health responsibility to support harmonization

More Related